SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 open-label extension data presented at the World Muscle Society is driving attention, with traders highlighting delayed-start results they believe show slower upper-limb decline on deramiocel. Many see the data as support for the pending FDA review, while others question whether the open-label evidence and disputed statistical analysis will satisfy regulators; approval expectations and short-squeeze speculation remain unconfirmed.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods product-expansion announcementsincluding planned 24/7 stock trading, perpetual futures and new social featuresare fueling discussion, with some traders welcoming broader access while others criticize the presentation and worry about round-the-clock, leveraged trading. Complaints about a separate app outage and frustration with the stocks price action add to the mixed reaction.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming fiscal Q4 report is the dominant focus, especially what its guidance says about memory pricing, AI-driven HBM and DRAM demand, and how long tight supply may last. Traders are hopeful for strong results but debate whether high expectations are already priced in, with concerns about a sell-the-news reaction and the durability of the memory cycle.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised FY2026 revenue outlook, driven by stronger demand for Amtagvi and Proleukin, sparked a sharp rally and renewed confidence in its commercial growth. Traders are broadly bullish and speculate that heavy short interest could amplify the move, while others warn about overvaluation, profit-taking, and possible dilution; upcoming lung-cancer data is also a focus.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are under pressure amid concerns about slowing growth, weaker advertising demand and competition from Amazon and automated ad platforms. Traders are split between seeing the companys cash generation and low valuation as support and expecting further declines, with many criticizing management and a smaller group anticipating a rebound.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A pause in the federal marijuana-rescheduling hearing tied to a GAO report on gaps in drug-scheduling procedures has renewed concerns about delays to the potential move to Schedule III. Traders are split between fearing the delay removes a near-term catalyst and calling the selloff an overreaction because the rescheduling process remains underway.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

A 737 MAX flight-guidance software glitch and the FAAs review have put Boeings MAX 10 certification and delivery outlook under scrutiny. Traders are split between viewing the issue as a manageable, fixable problem and seeing another setback to Boeings safety and execution recovery.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas positive Phase 3 results for HETLIOZ in delayed sleep-wake phase disorder are drawing attention, with traders celebrating the trial outcome while questioning why the stock has not responded more strongly. Some also view the result as adding to Vandas pipeline and potential buyout appeal, though that remains speculation.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Rising Treasury yields and oil-related inflation fears, alongside expectations of further Fed tightening, dominate discussion around the Dow-tracking ETF. Traders debate whether broad weakness and deteriorating market breadth point to deeper risk or whether resilient price action and dip-buying will prevail.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares plunged after FHFA changes put VantageScore alongside FICO on a single mortgage-pricing grid, while Rocket Mortgages planned preference for VantageScore and its lower pricing sharpened concerns about competition, mortgage-score revenue, and FICOs pricing power. Traders are split between viewing the move as a lasting erosion of FICOs market moat and calling the selloff an overreaction, with some looking for a rebound and others expecting further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The move appears tied to traders reaction to WMS posters on Capricors 24-month deramiocel data, especially a delayed-start analysis reporting slower PUL score decline after patients switched from placebo to treatment. Community discussion focused on the results as potentially supportive of the ongoing FDA review, though no news article independently verifies them.

CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) and reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class...

CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud LawsuitPR NewswireNEW YORK...

CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline

CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder...

SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR

SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPRPR...

CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS

Hagens Berman notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the September 28, 2026 lead plaintiff deadline in the pending securities class action.Submit Your CAPR Losses To HBSSKey DetailsClass Period: Dec. 17, 2025 July 26, 2026Lead Plaintiff Deadline: Sept. 28, 2026Visit...

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi...

CAPR Class Action: Capricor Therapeutics Investors are Notified of the Upcoming September 28 Deadline in Ongoing Securities Fraud Class Action over Clinical Data

CAPR Class Action: Capricor Therapeutics Investors are Notified of the Upcoming September 28 Deadline in Ongoing Securities Fraud Class Action over Clinical Data CAPR Class Action: Capricor Therapeutics Investors are Notified of the Upcoming September 28 Deadline in Ongoing Securities Fraud Class...

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Sept. 22, 2026 LOS ANGELES, Sept. 22, 2026 /PRNewswire...

Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision

Equity

Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

Investors are closely watching upcoming World Muscle Society presentation data and the potential impact on FDA approval odds.

Expectations remain high for a November FDA decision on deramiocel, with many bulls banking on positive efficacy data.

With over 50% short interest reported, traders are buzzing about a potential violent squeeze following positive trial results.

The community is vocalizing deep frustration over past FDA adcom decisions, labeling them inconsistent compared to other drug approvals.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAPR Capricor Therapeutics Inc

Fundamentals

Latest CAPR News